Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Lancet Respir Med
; 8(8): 775-785, 2020 08.
Article
in En
| MEDLINE
| ID: mdl-32109425
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrimidines
/
Sulfonamides
/
Chronic Disease
/
Cough
/
Purinergic P2X Receptor Antagonists
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
/
Europa
Language:
En
Journal:
Lancet Respir Med
Year:
2020
Document type:
Article
Country of publication: